Takeda Pharmaceutical (TAK) Earnings Analysis

Takeda Pharmaceutical (TAK) next reports earnings on 2026-07-30, consensus EPS 0.1689 USD. Last quarter (2026-01-29) it missed with EPS 0.48 USD vs 0.55 USD est (-12.7%). It has beaten estimates in 3/5 recent quarters (60%). Trailing P/E 45.13.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does TAK next report earnings?

Next earnings date2026-07-30
Consensus EPS estimate0.1689 USD
Revenue estimate7.15B

TAK earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-01-290.48 USD0.55 USD-12.7%Miss
2025-10-300.44 USD0.44 USD0%Beat
2025-07-300.52 USD0.47 USD+10.6%Beat
2025-01-300.42 USD0.63 USD-33.3%Miss
2024-10-310.44 USD0.39 USD+12.8%Beat

Beat rate: 3/5 (60%) over reported quarters with consensus data.

TAK valuation and analyst view

Trailing P/E45.13
Trailing EPS61.36 USD
Price / book1.11
Dividend yield3.63%
Market cap53.91B
Analyst consensusBuy (5 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is Takeda Pharmaceutical (TAK)'s next earnings date?

Takeda Pharmaceutical is next scheduled to report on 2026-07-30, with a consensus EPS estimate of 0.1689 USD and revenue estimate of 7.15B.

Did TAK beat earnings last quarter?

In its 2026-01-29 report, TAK posted EPS of 0.48 USD versus a 0.55 USD estimate — a miss of 12.7%.

What is TAK's earnings track record?

Over the last 5 reported quarters with consensus data, TAK beat estimates 3 times (60%).

What is TAK's current P/E ratio and EPS?

TAK trades at a trailing P/E of 45.13 on trailing EPS of 61.36 USD.

What do analysts rate TAK?

Analyst consensus is "Buy" across 6 ratings (0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell).